VEGFA and hepatocellular carcinoma: Another study showed that HCC patients who were refractory to sorafenib treatment had higher circulating cell-free DNA (cfDNA) levels of VEGF and that the group with cfDNA levels of VEGF above the median had worse time to progression (TTP) [130].